Novel Coronavirus (COVID-19) Vaccine Market Report

China Novel Coronavirus (COVID-19) Vaccine Industry Market Research Report 2023-2029

  • POSTDATE：Aug 19, 2023
  • PAGES：235
  • REPORT CODE：GMM1742725
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • This report elaborates on the current development of the Novel Coronavirus (COVID-19) Vaccine industry thoroughly based on the international market dynamics and China's market situation.

    For a start, the report provides an in-depth analysis of the current market situation through three different aspects - by region, by type and by application, which includes market distribution of different types and applications, import and export analysis of major regions, development trends of different types of products in each region, market opportunities and market restrains of different applications.

    Secondly, this report lists the major players in the industry, displaying their market positions and strengths and weaknesses of their products, picturing the current competitive situation of the whole market. 

    Last but not least, the report analyzes and predicts the investment prospects and risks in the industry on the basis of industry data, combined with experts' opinions and suggestions.

    By Player:

    • BioNTech

    • AnGes

    • EuBiologics

    • Medicago

    • Sinopharm

    • Pfizer

    • GlaxoSmithKline

    • Valneva

    • CanSinoBio

    • CureVac

    • Genexine

    • Symvivo

    • Heat Biologics

    • Moderna

    • Bharat Biotech

    • Zydus Cadila

    • Novavax

    • AIVITA Biomedical

    • INOVIO

    • AstraZeneca

    • GreenLight Biosciences

    • Sinovac

    • IIBR

    • Gennova

    By Type:

    • Protein Subunit Vaccine

    • mRNA Vaccine

    • Viral Vector Vaccine

    By Application:

    • Mild Symptom Patient

    • Critically Ill Patient

    By Research Region:

    • North China

    • Central China

    • South China

    • East China

    • Northeast China

    • Southwest China

    • Northwest China

  • TABLE OF CONTENT

    Chapter 1 China Novel Coronavirus (COVID-19) Vaccine Market Overview 2018-2029

    • 1.1 China Novel Coronavirus (COVID-19) Vaccine Industry Development Overview

    • 1.2 China Novel Coronavirus (COVID-19) Vaccine Industry Development History

    • 1.3 China Novel Coronavirus (COVID-19) Vaccine Industry Market Size (2018-2029)

    • 1.4 China Novel Coronavirus (COVID-19) Vaccine Market Analysis by Type from Production Side

      • 1.4.1 China Novel Coronavirus (COVID-19) Vaccine Production Volume, Production Value and Growth Rate of Protein Subunit Vaccine (2018-2029)

      • 1.4.2 China Novel Coronavirus (COVID-19) Vaccine Production Volume, Production Value and Growth Rate of mRNA Vaccine (2018-2029)

      • 1.4.3 China Novel Coronavirus (COVID-19) Vaccine Production Volume, Production Value and Growth Rate of Viral Vector Vaccine (2018-2029)

    • 1.5 China Novel Coronavirus (COVID-19) Vaccine Market Analysis by Application from Consumption End

      • 1.5.1 China Novel Coronavirus (COVID-19) Vaccine Sales Volume, Sales Value and Growth Rate of Mild Symptom Patient (2018-2029)

      • 1.5.2 China Novel Coronavirus (COVID-19) Vaccine Sales Volume, Sales Value and Growth Rate of Critically Ill Patient (2018-2029)

    • 1.6 China Novel Coronavirus (COVID-19) Vaccine Market Analysis by Region

      • 1.6.1 North China Novel Coronavirus (COVID-19) Vaccine Market Size and Growth Rate from 2018-2029

      • 1.6.2 Central China Novel Coronavirus (COVID-19) Vaccine Market Size and Growth Rate from 2018-2029

      • 1.6.3 South China Novel Coronavirus (COVID-19) Vaccine Market Size and Growth Rate from 2018-2029

      • 1.6.4 East China Novel Coronavirus (COVID-19) Vaccine Market Size and Growth Rate from 2018-2029

      • 1.6.5 Northeast China Novel Coronavirus (COVID-19) Vaccine Market Size and Growth Rate from 2018-2029

      • 1.6.6 Southwest China Novel Coronavirus (COVID-19) Vaccine Market Size and Growth Rate from 2018-2029

      • 1.6.7 Northwest China Novel Coronavirus (COVID-19) Vaccine Market Size and Growth Rate from 2018-2029

    Chapter 2 China Novel Coronavirus (COVID-19) Vaccine Industry Development Environment

    • 2.1 Industry Development Environment Analysis

      • 2.1.1 Industry Technological Progress Analysis

      • 2.1.2 Industrial Organizational Innovation Analysis

      • 2.1.3 Changes in Social Habits

      • 2.1.4 Alterations in Government Policies

      • 2.1.5 Impact of Economic Globalization

    • 2.2 Domestic and Foreign Industry Competition Analysis

      • 2.2.1 Comparative Analysis on Novel Coronavirus (COVID-19) Vaccine Market Status and Competition at home and abroad in 2023

      • 2.2.2 China Novel Coronavirus (COVID-19) Vaccine Market Status and Competition Analysis in 2023

      • 2.2.3 China Novel Coronavirus (COVID-19) Vaccine Market Concentration Analysis in 2023

    • 2.3 Problems and Countermeasures in the development of China Novel Coronavirus (COVID-19) Vaccine Industry

      • 2.3.1 Industry Development Constraints

      • 2.3.2 Industry Development Considerations

      • 2.3.3 Suggestions on Industry Development Measures

      • 2.3.4 Development Strategies for SMEs

    • 2.4 Influence of COVID-19 Outbreak on Novel Coronavirus (COVID-19) Vaccine Industry Development

    Chapter 3 Novel Coronavirus (COVID-19) VaccineIndustry Chain Analysis

    • 3.1 Novel Coronavirus (COVID-19) Vaccine Industry Chain

    • 3.2 Novel Coronavirus (COVID-19) Vaccine Upstream Industry Analysis

      • 3.2.1 Upstream Industry Development Status

      • 3.2.2 Upstream Industry Development Forecast

      • 3.2.3 Impact of Upstream Industry on the Novel Coronavirus (COVID-19) Vaccine Market

    • 3.3 Novel Coronavirus (COVID-19) Vaccine Downstream Industry Analysis

      • 3.3.1 Downstream Industry Development Status

      • 3.3.2 Downstream Industry Development Forecast

      • 3.3.3 Impact of Downstream Industry on the Novel Coronavirus (COVID-19) Vaccine Market

    Chapter 4 China Novel Coronavirus (COVID-19) Vaccine Market, by Type

    • 4.1 China Novel Coronavirus (COVID-19) Vaccine Market Trend, by Type

    • 4.2 Product Types of Major Suppliers

    • 4.3 Competitive Landscape of Major Types

    • 4.4 China Novel Coronavirus (COVID-19) Vaccine Total Production Volume and Growth Rate from Production Side

    • 4.5 China Novel Coronavirus (COVID-19) Vaccine Production Volume and Growth Rate, by Type

      • 4.5.1 China Novel Coronavirus (COVID-19) Vaccine Production Volume and Growth Rate of Protein Subunit Vaccine

      • 4.5.2 China Novel Coronavirus (COVID-19) Vaccine Production Volume and Growth Rate of mRNA Vaccine

      • 4.5.3 China Novel Coronavirus (COVID-19) Vaccine Production Volume and Growth Rate of Viral Vector Vaccine

    Chapter 5 China Novel Coronavirus (COVID-19) Vaccine Market, by Application

    • 5.1 Downstream Market Overview

    • 5.2 Competitive Landscape of Major Applications

    • 5.3 Market Potential Analysis, by Application

    • 5.4 China Novel Coronavirus (COVID-19) Vaccine Total Market Size and Growth Rate from Consumption End

    • 5.5 China Novel Coronavirus (COVID-19) Vaccine Market Size and Growth Rate, by Application

      • 5.5.1 China Novel Coronavirus (COVID-19) Vaccine Market Size and Growth Rate of Mild Symptom Patient

      • 5.5.2 China Novel Coronavirus (COVID-19) Vaccine Market Size and Growth Rate of Critically Ill Patient

    Chapter 6 China Novel Coronavirus (COVID-19) Vaccine Market, by Region

    • 6.1 China Novel Coronavirus (COVID-19) Vaccine Production Volume and Production Value, by Region

    • 6.2 China Novel Coronavirus (COVID-19) Vaccine Sales Volume and Sales Value, by Region

    Chapter 7 North China Novel Coronavirus (COVID-19) Vaccine Market Analysis

    • 7.1 North China Novel Coronavirus (COVID-19) Vaccine Market, by Type

    • 7.2 North China Novel Coronavirus (COVID-19) Vaccine Market, by Application

    Chapter 8 Central China Novel Coronavirus (COVID-19) Vaccine Market Analysis

    • 8.1 Central China Novel Coronavirus (COVID-19) Vaccine Market, by Type

    • 8.2 Central China Novel Coronavirus (COVID-19) Vaccine Market, by Application

    Chapter 9 South China Novel Coronavirus (COVID-19) Vaccine Market Analysis

    • 9.1 South China Novel Coronavirus (COVID-19) Vaccine Market, by Type

    • 9.2 South China Novel Coronavirus (COVID-19) Vaccine Market, by Application

    Chapter 10 East China Novel Coronavirus (COVID-19) Vaccine Market Analysis

    • 10.1 East China Novel Coronavirus (COVID-19) Vaccine Market, by Type

    • 10.2 East China Novel Coronavirus (COVID-19) Vaccine Market, by Application

    Chapter 11 Northeast China Novel Coronavirus (COVID-19) Vaccine Market Analysis

    • 11.1 Northeast China Novel Coronavirus (COVID-19) Vaccine Market, by Type

    • 11.2 Northeast China Novel Coronavirus (COVID-19) Vaccine Market, by Application

    Chapter 12 Southwest China Novel Coronavirus (COVID-19) Vaccine Market Analysis

    • 12.1 Southwest China Novel Coronavirus (COVID-19) Vaccine Market, by Type

    • 12.2 Southwest China Novel Coronavirus (COVID-19) Vaccine Market, by Application

    Chapter 13 Northwest China Novel Coronavirus (COVID-19) Vaccine Market Analysis

    • 13.1 Northwest China Novel Coronavirus (COVID-19) Vaccine Market, by Type

    • 13.2 Northwest China Novel Coronavirus (COVID-19) Vaccine Market, by Application

    Chapter 14 Company Profiles

      • 14.1 BioNTech

        • 14.1.1 BioNTech Company Profile

        • 14.1.2 BioNTech Novel Coronavirus (COVID-19) Vaccine Market Performance

        • 14.1.3 Product&Service Introduction

      • 14.2 AnGes

        • 14.2.1 AnGes Company Profile

        • 14.2.2 AnGes Novel Coronavirus (COVID-19) Vaccine Market Performance

        • 14.2.3 Product&Service Introduction

      • 14.3 EuBiologics

        • 14.3.1 EuBiologics Company Profile

        • 14.3.2 EuBiologics Novel Coronavirus (COVID-19) Vaccine Market Performance

        • 14.3.3 Product&Service Introduction

      • 14.4 Medicago

        • 14.4.1 Medicago Company Profile

        • 14.4.2 Medicago Novel Coronavirus (COVID-19) Vaccine Market Performance

        • 14.4.3 Product&Service Introduction

      • 14.5 Sinopharm

        • 14.5.1 Sinopharm Company Profile

        • 14.5.2 Sinopharm Novel Coronavirus (COVID-19) Vaccine Market Performance

        • 14.5.3 Product&Service Introduction

      • 14.6 Pfizer

        • 14.6.1 Pfizer Company Profile

        • 14.6.2 Pfizer Novel Coronavirus (COVID-19) Vaccine Market Performance

        • 14.6.3 Product&Service Introduction

      • 14.7 GlaxoSmithKline

        • 14.7.1 GlaxoSmithKline Company Profile

        • 14.7.2 GlaxoSmithKline Novel Coronavirus (COVID-19) Vaccine Market Performance

        • 14.7.3 Product&Service Introduction

      • 14.8 Valneva

        • 14.8.1 Valneva Company Profile

        • 14.8.2 Valneva Novel Coronavirus (COVID-19) Vaccine Market Performance

        • 14.8.3 Product&Service Introduction

      • 14.9 CanSinoBio

        • 14.9.1 CanSinoBio Company Profile

        • 14.9.2 CanSinoBio Novel Coronavirus (COVID-19) Vaccine Market Performance

        • 14.9.3 Product&Service Introduction

      • 14.10 CureVac

        • 14.10.1 CureVac Company Profile

        • 14.10.2 CureVac Novel Coronavirus (COVID-19) Vaccine Market Performance

        • 14.10.3 Product&Service Introduction

      • 14.11 Genexine

        • 14.11.1 Genexine Company Profile

        • 14.11.2 Genexine Novel Coronavirus (COVID-19) Vaccine Market Performance

        • 14.11.3 Product&Service Introduction

      • 14.12 Symvivo

        • 14.12.1 Symvivo Company Profile

        • 14.12.2 Symvivo Novel Coronavirus (COVID-19) Vaccine Market Performance

        • 14.12.3 Product&Service Introduction

      • 14.13 Heat Biologics

        • 14.13.1 Heat Biologics Company Profile

        • 14.13.2 Heat Biologics Novel Coronavirus (COVID-19) Vaccine Market Performance

        • 14.13.3 Product&Service Introduction

      • 14.14 Moderna

        • 14.14.1 Moderna Company Profile

        • 14.14.2 Moderna Novel Coronavirus (COVID-19) Vaccine Market Performance

        • 14.14.3 Product&Service Introduction

      • 14.15 Bharat Biotech

        • 14.15.1 Bharat Biotech Company Profile

        • 14.15.2 Bharat Biotech Novel Coronavirus (COVID-19) Vaccine Market Performance

        • 14.15.3 Product&Service Introduction

      • 14.16 Zydus Cadila

        • 14.16.1 Zydus Cadila Company Profile

        • 14.16.2 Zydus Cadila Novel Coronavirus (COVID-19) Vaccine Market Performance

        • 14.16.3 Product&Service Introduction

      • 14.17 Novavax

        • 14.17.1 Novavax Company Profile

        • 14.17.2 Novavax Novel Coronavirus (COVID-19) Vaccine Market Performance

        • 14.17.3 Product&Service Introduction

      • 14.18 AIVITA Biomedical

        • 14.18.1 AIVITA Biomedical Company Profile

        • 14.18.2 AIVITA Biomedical Novel Coronavirus (COVID-19) Vaccine Market Performance

        • 14.18.3 Product&Service Introduction

      • 14.19 INOVIO

        • 14.19.1 INOVIO Company Profile

        • 14.19.2 INOVIO Novel Coronavirus (COVID-19) Vaccine Market Performance

        • 14.19.3 Product&Service Introduction

      • 14.20 AstraZeneca

        • 14.20.1 AstraZeneca Company Profile

        • 14.20.2 AstraZeneca Novel Coronavirus (COVID-19) Vaccine Market Performance

        • 14.20.3 Product&Service Introduction

      • 14.21 GreenLight Biosciences

        • 14.21.1 GreenLight Biosciences Company Profile

        • 14.21.2 GreenLight Biosciences Novel Coronavirus (COVID-19) Vaccine Market Performance

        • 14.21.3 Product&Service Introduction

      • 14.22 Sinovac

        • 14.22.1 Sinovac Company Profile

        • 14.22.2 Sinovac Novel Coronavirus (COVID-19) Vaccine Market Performance

        • 14.22.3 Product&Service Introduction

      • 14.23 IIBR

        • 14.23.1 IIBR Company Profile

        • 14.23.2 IIBR Novel Coronavirus (COVID-19) Vaccine Market Performance

        • 14.23.3 Product&Service Introduction

      • 14.24 Gennova

        • 14.24.1 Gennova Company Profile

        • 14.24.2 Gennova Novel Coronavirus (COVID-19) Vaccine Market Performance

        • 14.24.3 Product&Service Introduction

    Chapter 15 Research Conclusions and Investment Suggestions

    • 15.1 Novel Coronavirus (COVID-19) Vaccine Industry Research Conclusions

    • 15.2 Novel Coronavirus (COVID-19) Vaccine Industry Investment Suggestions

      • 15.2.1 Suggestions on Industry Development Strategy

      • 15.2.2 Suggestions on Industry Investment Direction

      • 15.2.3 Suggestions on Industry Investment Strategy


    List of Tables and Figures

    • Figure China Novel Coronavirus (COVID-19) Vaccine Industry Market Size (2018-2029)

    • Figure China Novel Coronavirus (COVID-19) Vaccine Production Volume, Production Value and Growth Rate of Protein Subunit Vaccine (2018-2029)

    • Figure China Novel Coronavirus (COVID-19) Vaccine Production Volume, Production Value and Growth Rate of mRNA Vaccine (2018-2029)

    • Figure China Novel Coronavirus (COVID-19) Vaccine Production Volume, Production Value and Growth Rate of Viral Vector Vaccine (2018-2029)

    • Figure China Novel Coronavirus (COVID-19) Vaccine Sales Volume, Sales Value and Growth Rate of Mild Symptom Patient (2018-2029)

    • Figure China Novel Coronavirus (COVID-19) Vaccine Sales Volume, Sales Value and Growth Rate of Critically Ill Patient (2018-2029)

    • Figure North China Novel Coronavirus (COVID-19) Vaccine Market Size and Growth Rate from 2018-2029

    • Figure Central China Novel Coronavirus (COVID-19) Vaccine Market Size and Growth Rate from 2018-2029

    • Figure South China Novel Coronavirus (COVID-19) Vaccine Market Size and Growth Rate from 2018-2029

    • Figure East China Novel Coronavirus (COVID-19) Vaccine Market Size and Growth Rate from 2018-2029

    • Figure Northeast China Novel Coronavirus (COVID-19) Vaccine Market Size and Growth Rate from 2018-2029

    • Figure Southwest China Novel Coronavirus (COVID-19) Vaccine Market Size and Growth Rate from 2018-2029

    • Figure Northwest China Novel Coronavirus (COVID-19) Vaccine Market Size and Growth Rate from 2018-2029

    • Figure Novel Coronavirus (COVID-19) Vaccine Industry Chain

    • Table Product Types of Major Suppliers in 2023

    • Figure China Novel Coronavirus (COVID-19) Vaccine Market Share by Type in 2018

    • Figure China Novel Coronavirus (COVID-19) Vaccine Market Share by Type in 2023

    • Figure China Novel Coronavirus (COVID-19) Vaccine Total Production Volume and Growth Rate from Production Side (2018-2023)

    • Figure China Novel Coronavirus (COVID-19) Vaccine Production Volume and Growth Rate of Protein Subunit Vaccine (2018-2023)

    • Figure China Novel Coronavirus (COVID-19) Vaccine Production Volume and Growth Rate of mRNA Vaccine (2018-2023)

    • Figure China Novel Coronavirus (COVID-19) Vaccine Production Volume and Growth Rate of Viral Vector Vaccine (2018-2023)

    • Figure China Novel Coronavirus (COVID-19) Vaccine Market Share by Application in 2018

    • Figure China Novel Coronavirus (COVID-19) Vaccine Market Share by Application in 2023

    • Figure China Novel Coronavirus (COVID-19) Vaccine Total Market Size and Growth Rate from Consumption End

    • Figure China Novel Coronavirus (COVID-19) Vaccine Market Size and Growth Rate of Mild Symptom Patient (2018-2023)

    • Figure China Novel Coronavirus (COVID-19) Vaccine Market Size and Growth Rate of Critically Ill Patient (2018-2023)

    • Table China Novel Coronavirus (COVID-19) Vaccine Production Volume by Region (2018-2023)

    • Table China Novel Coronavirus (COVID-19) Vaccine Production Volume Share by Region (2018-2023)

    • Figure China Novel Coronavirus (COVID-19) Vaccine Production Volume Share by Region (2018-2023)

    • Table China Novel Coronavirus (COVID-19) Vaccine Production Value by Region (2018-2023)

    • Table China Novel Coronavirus (COVID-19) Vaccine Production Value Share by Region (2018-2023)

    • Figure China Novel Coronavirus (COVID-19) Vaccine Production Value Share by Region (2018-2023)

    • Table China Novel Coronavirus (COVID-19) Vaccine Sales Volume by Region (2018-2023)

    • Table China Novel Coronavirus (COVID-19) Vaccine Sales Volume Share by Region (2018-2023)

    • Figure China Novel Coronavirus (COVID-19) Vaccine Sales Volume Share by Region (2018-2023)

    • Table China Novel Coronavirus (COVID-19) Vaccine Sales Value by Region (2018-2023)

    • Table China Novel Coronavirus (COVID-19) Vaccine Sales Value Share by Region (2018-2023)

    • Figure China Novel Coronavirus (COVID-19) Vaccine Sales Value Share by Region (2018-2023)

    • Table North China Novel Coronavirus (COVID-19) Vaccine Production Volume by Type (2018-2023)

    • Table North China Novel Coronavirus (COVID-19) Vaccine Production Volume Share by Type (2018-2023)

    • Figure North China Novel Coronavirus (COVID-19) Vaccine Production Volume Share by Type (2018-2023)

    • Table North China Novel Coronavirus (COVID-19) Vaccine Sales Volume by Application (2018-2023)

    • Table North China Novel Coronavirus (COVID-19) Vaccine Sales Volume Share by Application (2018-2023)

    • Figure North China Novel Coronavirus (COVID-19) Vaccine Sales Volume Share by Application (2018-2023)

    • Table Central China Novel Coronavirus (COVID-19) Vaccine Production Volume by Type (2018-2023)

    • Table Central China Novel Coronavirus (COVID-19) Vaccine Production Volume Share by Type (2018-2023)

    • Figure Central China Novel Coronavirus (COVID-19) Vaccine Production Volume Share by Type (2018-2023)

    • Table Central China Novel Coronavirus (COVID-19) Vaccine Sales Volume by Application (2018-2023)

    • Table Central China Novel Coronavirus (COVID-19) Vaccine Sales Volume Share by Application (2018-2023)

    • Figure Central China Novel Coronavirus (COVID-19) Vaccine Sales Volume Share by Application (2018-2023)

    • Table South China Novel Coronavirus (COVID-19) Vaccine Production Volume by Type (2018-2023)

    • Table South China Novel Coronavirus (COVID-19) Vaccine Production Volume Share by Type (2018-2023)

    • Figure South China Novel Coronavirus (COVID-19) Vaccine Production Volume Share by Type (2018-2023)

    • Table South China Novel Coronavirus (COVID-19) Vaccine Sales Volume by Application (2018-2023)

    • Table South China Novel Coronavirus (COVID-19) Vaccine Sales Volume Share by Application (2018-2023)

    • Figure South China Novel Coronavirus (COVID-19) Vaccine Sales Volume Share by Application (2018-2023)

    • Table East China Novel Coronavirus (COVID-19) Vaccine Production Volume by Type (2018-2023)

    • Table East China Novel Coronavirus (COVID-19) Vaccine Production Volume Share by Type (2018-2023)

    • Figure East China Novel Coronavirus (COVID-19) Vaccine Production Volume Share by Type (2018-2023)

    • Table East China Novel Coronavirus (COVID-19) Vaccine Sales Volume by Application (2018-2023)

    • Table East China Novel Coronavirus (COVID-19) Vaccine Sales Volume Share by Application (2018-2023)

    • Figure East China Novel Coronavirus (COVID-19) Vaccine Sales Volume Share by Application (2018-2023)

    • Table Northeast China Novel Coronavirus (COVID-19) Vaccine Production Volume by Type (2018-2023)

    • Table Northeast China Novel Coronavirus (COVID-19) Vaccine Production Volume Share by Type (2018-2023)

    • Figure Northeast China Novel Coronavirus (COVID-19) Vaccine Production Volume Share by Type (2018-2023)

    • Table Northeast China Novel Coronavirus (COVID-19) Vaccine Sales Volume by Application (2018-2023)

    • Table Northeast China Novel Coronavirus (COVID-19) Vaccine Sales Volume Share by Application (2018-2023)

    • Figure Northeast China Novel Coronavirus (COVID-19) Vaccine Sales Volume Share by Application (2018-2023)

    • Table Southwest China Novel Coronavirus (COVID-19) Vaccine Production Volume by Type (2018-2023)

    • Table Southwest China Novel Coronavirus (COVID-19) Vaccine Production Volume Share by Type (2018-2023)

    • Figure Southwest China Novel Coronavirus (COVID-19) Vaccine Production Volume Share by Type (2018-2023)

    • Table Southwest China Novel Coronavirus (COVID-19) Vaccine Sales Volume by Application (2018-2023)

    • Table Southwest China Novel Coronavirus (COVID-19) Vaccine Sales Volume Share by Application (2018-2023)

    • Figure Southwest China Novel Coronavirus (COVID-19) Vaccine Sales Volume Share by Application (2018-2023)

    • Table Northwest China Novel Coronavirus (COVID-19) Vaccine Production Volume by Type (2018-2023)

    • Table Northwest China Novel Coronavirus (COVID-19) Vaccine Production Volume Share by Type (2018-2023)

    • Figure Northwest China Novel Coronavirus (COVID-19) Vaccine Production Volume Share by Type (2018-2023)

    • Table Northwest China Novel Coronavirus (COVID-19) Vaccine Sales Volume by Application (2018-2023)

    • Table Northwest China Novel Coronavirus (COVID-19) Vaccine Sales Volume Share by Application (2018-2023)

    • Figure Northwest China Novel Coronavirus (COVID-19) Vaccine Sales Volume Share by Application (2018-2023)

    • Table BioNTech Company Profile

    • Table BioNTech Novel Coronavirus (COVID-19) Vaccine Revenue, Price and Gross (2018-2023)

    • Table AnGes Company Profile

    • Table AnGes Novel Coronavirus (COVID-19) Vaccine Revenue, Price and Gross (2018-2023)

    • Table EuBiologics Company Profile

    • Table EuBiologics Novel Coronavirus (COVID-19) Vaccine Revenue, Price and Gross (2018-2023)

    • Table Medicago Company Profile

    • Table Medicago Novel Coronavirus (COVID-19) Vaccine Revenue, Price and Gross (2018-2023)

    • Table Sinopharm Company Profile

    • Table Sinopharm Novel Coronavirus (COVID-19) Vaccine Revenue, Price and Gross (2018-2023)

    • Table Pfizer Company Profile

    • Table Pfizer Novel Coronavirus (COVID-19) Vaccine Revenue, Price and Gross (2018-2023)

    • Table GlaxoSmithKline Company Profile

    • Table GlaxoSmithKline Novel Coronavirus (COVID-19) Vaccine Revenue, Price and Gross (2018-2023)

    • Table Valneva Company Profile

    • Table Valneva Novel Coronavirus (COVID-19) Vaccine Revenue, Price and Gross (2018-2023)

    • Table CanSinoBio Company Profile

    • Table CanSinoBio Novel Coronavirus (COVID-19) Vaccine Revenue, Price and Gross (2018-2023)

    • Table CureVac Company Profile

    • Table CureVac Novel Coronavirus (COVID-19) Vaccine Revenue, Price and Gross (2018-2023)

    • Table Genexine Company Profile

    • Table Genexine Novel Coronavirus (COVID-19) Vaccine Revenue, Price and Gross (2018-2023)

    • Table Symvivo Company Profile

    • Table Symvivo Novel Coronavirus (COVID-19) Vaccine Revenue, Price and Gross (2018-2023)

    • Table Heat Biologics Company Profile

    • Table Heat Biologics Novel Coronavirus (COVID-19) Vaccine Revenue, Price and Gross (2018-2023)

    • Table Moderna Company Profile

    • Table Moderna Novel Coronavirus (COVID-19) Vaccine Revenue, Price and Gross (2018-2023)

    • Table Bharat Biotech Company Profile

    • Table Bharat Biotech Novel Coronavirus (COVID-19) Vaccine Revenue, Price and Gross (2018-2023)

    • Table Zydus Cadila Company Profile

    • Table Zydus Cadila Novel Coronavirus (COVID-19) Vaccine Revenue, Price and Gross (2018-2023)

    • Table Novavax Company Profile

    • Table Novavax Novel Coronavirus (COVID-19) Vaccine Revenue, Price and Gross (2018-2023)

    • Table AIVITA Biomedical Company Profile

    • Table AIVITA Biomedical Novel Coronavirus (COVID-19) Vaccine Revenue, Price and Gross (2018-2023)

    • Table INOVIO Company Profile

    • Table INOVIO Novel Coronavirus (COVID-19) Vaccine Revenue, Price and Gross (2018-2023)

    • Table AstraZeneca Company Profile

    • Table AstraZeneca Novel Coronavirus (COVID-19) Vaccine Revenue, Price and Gross (2018-2023)

    • Table GreenLight Biosciences Company Profile

    • Table GreenLight Biosciences Novel Coronavirus (COVID-19) Vaccine Revenue, Price and Gross (2018-2023)

    • Table Sinovac Company Profile

    • Table Sinovac Novel Coronavirus (COVID-19) Vaccine Revenue, Price and Gross (2018-2023)

    • Table IIBR Company Profile

    • Table IIBR Novel Coronavirus (COVID-19) Vaccine Revenue, Price and Gross (2018-2023)

    • Table Gennova Company Profile

    • Table Gennova Novel Coronavirus (COVID-19) Vaccine Revenue, Price and Gross (2018-2023)


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US